Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 25 Apr 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary) ; Sirolimus (Primary)
Indications Cardiovascular disorders; Coronary artery disease; Coronary artery restenosis
Focus Therapeutic Use
Acronyms FREEDOM

19 Apr 2022 Data from this trial was used predict different outcomes with CABG vs PCI for SYNTAX and BEST trials. Results assessing the ability of the 5-year major adverse cardiovascular event (MACE) model to predict treatment benefit of CABG vs PCI in the SYNTAX and BEST trials published in the Journal of the American College of Cardiology
01 Nov 2018 Results published in the Journal of the American College of Cardiology
17 Jan 2017 Results of post hoc secondary analysis published in the Journal of the American College of Cardiology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com